HomeExamplesDataResearchDocumentationLoginBook a demo
HomeExamplesDataResearchDocumentationLoginBook a demo

Agyany Pharma

Ownership
Private
Therapeutic Areas
Neurology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules

Agyany Pharma General Information

Agyany is developing treatments for Parkinson's disease, focusing on ambroxol as a pharmacological chaperon for GBA1-related Parkinson's. The company plans to begin clinical trials in newly diagnosed PD patients using existing generic drugs, aiming to provide a shorter path to novel therapeutic approaches for both GBA-related PD and potentially idiopathic PD[5][6].

Contact Information

Website
https://www.agyanypharma.com/
Primary Industry
Biotech
Corporate Office
Jerusalem,
Israel

Drug Pipeline

ambroxol
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Agyany Pharma's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Agyany Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Agyany Pharma's complete valuation and funding history, request access »

Agyany Pharma Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals